Ligand Pharmaceuticals (LGND) Current Leases (2010 - 2026)

Ligand Pharmaceuticals has disclosed Current Leases across 15 years of filings, most recently posting $1.1 million for Q1 2026.

• Current Leases for Q1 2026 came in at $1.1 million, up 4433.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 4433.33% YoY), and the FY2025 annual result was $1.1 million, down 13.51% from the prior year.
• Current Leases came in at $1.1 million for Q1 2026 at Ligand Pharmaceuticals, down from $1.1 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.4 million in Q3 2022 to a low of $7000.0 in Q4 2023.
• The 5-year median for Current Leases is $497000.0 (2023), against an average of $613588.2.
• Peak annual rise in Current Leases reached 17985.71% in 2024, while the deepest fall reached 98.24% in 2024.
• Ligand Pharmaceuticals' Current Leases stood at $45000.0 in 2022, then sank by 84.44% to $7000.0 in 2023, then jumped by 17985.71% to $1.3 million in 2024, then fell by 13.51% to $1.1 million in 2025, then dropped by 0.64% to $1.1 million in 2026.
• The last three Current Leases figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.